This study is testing a drug called olverembatinib for people with newly diagnosed Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL), a type of fast-growing blood cancer. Researchers want to see how well olverembatinib, when given with chemotherapy, works compared to another standard treatment (investigator's choice of TKI, also with chemotherapy). Both olverembatinib and the other TKI are kinase inhibitors, meaning they block certain proteins that help cancer cells grow. The main goal is to see if the cancer disappears completely and stays gone (Minimal Residual Disease Negative CR Rate) after 1 to 3 cycles of treatment. You might be able to join if you are at least 18 years old, have newly diagnosed Ph+ ALL, and are generally healthy enough for treatment. The study plans to enroll 350 participants.

Study design

This is a global, multi-center, open-label (you and your doctors will know which treatment you are receiving), randomized Phase 3 study comparing two treatment approaches in 350 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured from Cycle 1 to Cycle 3 (each cycle is 28 days), but the overall follow-up duration is not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.